T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy
- T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy
- 류주희; 김한영; 강미경; 홍지혜; 정문교; 권성필; 송석영; 이주로; 강서경; 한진; 구자현; 임송현; 손희수; 최제민; 도준상; 김병수
- Issue Date
- Advanced materials
- VOL 32, NO 39-2003377
- Cancer immunotherapies, including adoptive T cell transfer and immune checkpoint blockades, have recently shown considerable success in cancer treatment. Nevertheless, transferred T cells often become exhausted because of the immunosuppressive tumor microenvironment. Immune checkpoint blockades, in contrast, can reinvigorate the exhausted T cells; however, the therapeutic efficacy is modest in 70？80% of patients. To address some of the challenges faced by the current cancer treatments, here Tcellmembranecoated nanoparticles (TCMNPs) are developed for cancer immunotherapy. Similar to cytotoxic T cells, TCMNPs can be targeted at tumors via Tcellmembraneoriginated proteins and kill cancer cells by releasing anticancer molecules and inducing Fasligandmediated apoptosis. Unlike cytotoxic T cells, TCMNPs are resistant to immunosuppressive molecules (e.g., transforming growth factorβ1 (TGFβ1)) and programmed deathligand 1 (PDL1) of cancer cells by scavenging TGFβ1 and PDL1. Indeed, TCMNPs exhibit higher therapeutic efficacy than an immune checkpoint blockade in melanoma treatment. Furthermore, the antitumoral actions of TCMNPs are also demonstrated in the treatment of lung cancer in an antigennonspecific manner. Taken together, TCMNPs have a potential to improve the current cancer immunotherapy.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.